Effectiveness of Fludarabine, Idarubicin and Cyclophosphamide (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin's Lymphoma
Authors:
- Pier Luigi ZinzaniPZPier Luigi Zinzani
- Alessandro PulsoniAPAlessandro Pulsoni
- Patrizia GentiliniPGPatrizia Gentilini
- Giuseppe VisaniGVGiuseppe Visani
- Alessio PerrottiAPAlessio Perrotti
- Anna Lia MolinariAMAnna Lia Molinari
- Luciano GuardigniLGLuciano Guardigni
- Monica TaniMTMonica Tani
- Nicoletta VillivàNVNicoletta Villivà
- Vittorio StefoniVSVittorio Stefoni
- Lapo AlinariLALapo Alinari
- Maurizio MartelliMMMaurizio Martelli
- 1 September 2004
- journal article
- clinical trial
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (9) , 1815-1819
Abstract
In the last years, fludarabine (FLU) alone or in combination with other drugs has been reported to be effective in the treatment of previously untreated low-grade non-Hodgkin's lymphomas (LG-NHL). We report on the therapeutic efficacy and toxicity of a combination of FLU, idarubicin and cyclophosphamide (FLUIC regimen) in untreated non-follicular LG-NHL. We administered a three-drug combination of FLU (25 mg/m2 i.v. on days 1 to 3), idarubicin (14 mg/m2 i.v. on day 1) and cyclophosphamide (200 mg/m2 i.v. on days 1 to 3) to treat 41 young, previously untreated patients with non-follicular LG-NHL. Chemotherapy was repeated every 4 weeks for a total of 6 cycles. Among 41 patients, 24 (59%) were diagnosed with small lymphocytic, 10 (24%) with immnocytoma, and 7 (17%) with marginal zone subtypes. Nineteen (46%) patients achieved complete response (CR) and 21 (51%) partial response, while the remaining 1 (3%) showed no benefit from the treatment. With respect to histology, we observed CR rates of 38% for the small lymphocytic subtype, 40% for the immunocytoma subtype, and 86% for the marginal zone subtype. Estimated 42-month overall survival and relapse-free survival rates were 64% and 100%, respectively. Hematologic grade 3-4 toxicity was seen in 9 (22%) patients; no opportunistic infection or death was associated with administration of the FLUIC regimen. These preliminary data suggest that FLUIC is a very active, well-tolerated regimen for young, untreated patients with advanced non-follicular LG-NHL.Keywords
This publication has 25 references indexed in Scilit:
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999
- FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low‐grade non‐Hodgkin's lymphomaEuropean Journal of Haematology, 1995
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pyloriThe Lancet, 1993
- Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphomaAnnals of Oncology, 1993
- Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.Journal of Clinical Oncology, 1992
- Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology, 1992
- Treatment of low‐grade non‐Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trialHematological Oncology, 1990
- The Natural History of Initially Untreated Low-Grade Non-Hodgkin's LymphomasNew England Journal of Medicine, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958